Nyrada (ASX:NYR) received human research ethics committee approval to modify its phase one clinical trial protocol, according to a Wednesday Australian bourse filing.
The amendments allow for the evaluation of the safety, tolerability, and pharmacokinetics of Xolatryp, a small-molecule cardioprotection and neuroprotection therapy candidate, in healthy volunteers at higher doses and over a longer infusion duration.
The phase one trial will consist of six cohorts, and results are expected in the September quarter.
The amended protocol will give the firm greater flexibility in designing a phase two trial, including the ability to optimize dosing for the target patient population, per the filing.
The firm's shares fell 3% in recent trading on Wednesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。